PBMs, Specialty Pharmacy Vendors Focus on High-Touch Rx Management Strategies Reprinted from , biweekly news, data and business strategies for health plans, PBMs and pharmaceutical companies.By Neal Learner, Managing Editor (nlearner@aispub.com) Health plans and other pharmaceutical payers increasingly say they...
FDA Approves Abbott's XIENCE V Drug Eluting Stent Tagged: Abbott Business Drugs FDA Pharmaceuticals XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease Abbott Park,...
Resolvyx Scientific Advisors Publish First In-Vivo Data Showing Resolvins Suppress IL-23 and IL-17, Key Mediat - Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that a research team led by a Resolvyx scientific advisor and a company co-founder has demonstrated that the resolvin E1 (RvE1) effectively...
Resolvyx Scientific Advisors Publish First In-Vivo Data Showing Resolvins Suppress IL-23 and IL-17, Key Mediat - Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that a research team led by a Resolvyx scientific advisor and a company co-founder has demonstrated that the resolvin E1 (RvE1) effectively...
Letters to the editor: July 14, 2008 A graduate intern working with me stated that in her pharmacy law class, she was informed that the consultation laws in Wisconsin have been changed so that the pharmacist now does not have to hand every Rx (including new Rxs if...
Automated dispensing, robots tapped to improve patient safety Drug Topics Supplements Pages | 1 | 2 Asteres' Linda Pinney says ADDMs can reduce Rx mix-ups While much pharmacy technology today is being touted as revolutionary in terms of enhancing productivity, streamlining pharmacy operations,...
This cross-country tour uncovers secrets to successful independent pharmacies Keansburg (N.J.) Pharmacy owns a 48,000-sq.-ft building and brings in extra revenue by leasing out 36,000 square feet.One of the most productive front end areas is a UPS shipping center.Thirteen days, 12 states, 4,187 miles, 30 pharmacies...
New products July 2008 Rx NEW DOSAGE The FDA has approved a new once-a-month dose of Actonel (risedronate sodium) tablets at 150 mg.The medication for the treatment and prevention of postmenopausal osteoporosis is approved to reduce the risk of fractures...
Resolvyx Scientific Advisors Publish First In-Vivo Data Showing Resolvins Suppress IL-23 and IL-17, Key Mediat Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that a research team led by a Resolvyx scientific advisor and a company co-founder has demonstrated that the resolvin E1 (RvE1) effectively suppresses...
Plug materials for pharma THERMOFORMING In cooperation with Montesino Associates LLC, a pharmaceutical packaging consulting firm, this firm has developed HYTAC-Rx, a syntactic plug-assist material developed solely for pharmaceutical blister packaging.HYTAC-...
Mylan gets tentative FDA OK for Linezolid tablets BOSTON (Thomson Financial) - Mylan Inc.said Thursday it has received tentaive approval from the Food and Drug Administration for Linezolid tablets.
Linezolid is the company's generic antibiotic version of Pharmacia and Upjohn's Zynvox...
Resolvyx Scientific Advisors Publish First In-Vivo Data Showing Resolvins Suppress IL-23 and IL-17, Key Mediat - Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that a research team led by a Resolvyx scientific advisor and a company co-founder has demonstrated that the resolvin E1 (RvE1) effectively...
COMMUNIQUE: PR Newswire: FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent - XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease Abbott today announced that the U.S.Food and Drug...
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott...
US advisers urge higher bar for new diabetes drugs SILVER SPRING, Md.(Reuters) - U.S.
regulators should require drugmakers to study the potential heart risks of all new diabetes medicines, an advisory panel said Wednesday.
The recommendation could force companies to run longer and...
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott...
Drug Approval Trends at the FDA and EMEA - Process improvements, heightened scrutiny and industry - www.companiesandmarkets.com adds new report - response Drug Approval Trends at the FDA and EMEA Business Intelligence for the Pharmaceutical Industry The healthcare management reports is designed to help you make well informed and timely...
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent ABBOTT PARK, Illinois, July 2 /PRNewswire/ -- - XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease Abbott today...
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S.Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S.Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S.Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S.Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S.Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent ABBOTTPARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S.Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S.Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
